National Institutes of Health (NIH)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
P40 Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Material Resource Grants
This Notice of Funding Opportunity (NOFO) encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals and associated services, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP’s NIH-wide mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Of special interest of the announcement is a requirement of the Center’s close coordination with efforts to develop new approach methodologies (NAMs) that complement traditional animal-based research. These include cell culture, organoids, computational models, and microphysiological systems. Applied Research Component should include studies to generate comparative data to increase applicability of NAMs and promote integration of the most predictive human disease models. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.
The Office of Research Infrastructure Programs (ORIP) is a program office in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) dedicated to supporting research infrastructure and related research resource programs. ORIP consists of the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI).
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| February 18, 2026 | February 18, 2026 | May 11, 2026 | July 2026 | October 2026 | December 2026 |
| May 27, 2026 | May 27, 2026 | September 09, 2026 | November 2026 | January 2027 | April 2027 |
| September 21, 2026 | September 21, 2026 | January 11, 2027 | March 2027 | May 2027 | July 2027 |
| January 26, 2027 | January 26, 2027 | May 10, 2027 | July 2027 | October 2027 | December 2027 |
| May 28, 2027 | May 28, 2027 | September 08, 2027 | November 2027 | January 2028 | April 2028 |
| September 28, 2027 | September 28, 2027 | January 10, 2028 | March 2028 | May 2028 | July 2028 |
| January 31, 2028 | January 31, 2028 | May 09, 2028 | July 2028 | October 2028 | December 2028 |
| May 30, 2028 | May 30, 2028 | September 11, 2028 | November 2028 | January 2029 | April 2029 |
| September 26, 2028 | September 26, 2028 | January 09, 2029 | March 2029 | May 2029 | July 2029 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
Objective
ORIP uses the P40 mechanism to support Animal and Biological Material Resource Centers in a variety of areas of biomedical science. Animal and Biological Material Resource Centers create, collect, develop, characterize, preserve, and distribute special colonies of high-quality and well-characterized laboratory animals and animal-related models. Special colonies of research animals are defined as animals that add value for biomedical research but are not generally available to investigators. Collecting, generating, and distributing such animals render these resources more accessible to the research community and eliminate costly redundant efforts. Other types of Animal and Biological Material Resource Centers provide informatics tools, data, analytical expertise, biological materials, or services that support research projects and that will enhance and expand an animal model system. Centers should emphasize use of broadly applicable, interdisciplinary validation tools to increase predictability of animal models, such as approaches to compare and determine relatedness and usefulness of a disease associated network/pathway/physiological process between an animal model and a human patient. Applications that heavily focus on building and maintaining genomic or phenotyping databases for individual animal species will not be considered for funding.
Of special interest of the announcement is a requirement of the Center’s close coordination with efforts to develop new approach methodologies (NAMs) that complement traditional animal-based research. These include cell culture, organoids, computational models, and microphysiological systems. NAMs enable research to be done more quickly, by more researchers, at a more affordable cost. Importantly, these advances are opening doors to complementary and more effective non-animal-based approaches for a variety of applications. The development of NAMs holds tremendous promise for increasing the tools available to achieve the NIH mission and potentially reduce and refine the future use of animals in some areas of research in the future. The Centers should promote integration with NAMs.
It is important that the community fully understand the strengths and limitations of these Centers, as well as areas of opportunity given the current state of science, that in turn will improve selection, design, and relevance of animal models.
Details concerning current Division of Comparative Medicine (DCM) Animal and Biological Material Resource Centers can be found at the following link: https://orip.nih.gov/resource-directory.
All applicants are strongly encouraged to consult with DCM Program staff on the appropriateness of the intended resource, competitiveness of a potential application, and whether the proposed application meets the goals and mission of the DCM/ORIP and is broad enough to serve the needs of the biomedical research community.
Examples of projects that WILL NOT be supported under this NOFO include those that:
Animal and Biological Material Resource Centers should have the following characteristics:
1) There should be a demonstrated need for the resource in the wider biomedical research community. Evidence of the depth and breadth of impact on a scientific community must be provided. Examples could include up to 15 letters of support from institutions, individuals, groups, or consortia; website usage; a statement from a scientific society; and/or a published white paper. Applications exceeding the 15 letters limit will be administratively withdrawn without review. Support letters from the institution submitting the P40 application are not counted towards this limit/cap.
2) The Centers should serve the needs of investigators in a variety of research areas where work is sponsored by multiple NIH ICs.
3) The Centers must be available and utilized by investigators on a national basis.
4) The Centers must ensure the quality and welfare of distributed animals and describe how their activities assist and promote optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research.
5) The Centers must have an Applied Research Component to generate new approaches or to enhance existing ones that will improve the resources and services provided to the community. Hypothesis driven R21- or R01-like research is not considered applied research. Applied Research Component should include studies to generate comparative data to increase applicability of NAMs and promote integration of the most predictive human disease models. The Applied Research Component may comprise no more than 15 percent of the direct costs associated with the P40 grant.
6) The Centers must have a Curation and Informatics component to support development and maintenance of in-house data management systems, curate stocks of animals and biomaterials, and maintain a searchable web portal with an integrated client friendly request/ordering system and outreach presentations.
7) The Institution submitting the P40 application must be committed to the Center being proposed. Evidence of such support must be provided. The application should include a letter of support from the Institution.
8) A critical component of improving scientific reproducibility of the research is to develop approaches for unique identification of research resources in public databases, including publications. The Center should register catalogs of their resources with current resource tagging and identification initiatives, such as FORCE 11 (https://www.force11.org/group/resource-identification-initiative). The Center should also work with the investigators to encourage the use of a resource identification system in their publications and reports.
9) The Centers required to develop approaches to maintain critical resources in reliable and cost-effective ways. Long-term preservation of the genetic stock of animal models is needed to ensure efficiency, rigor, and reproducibility in biomedical research. Cryopreservation of the germplasm should be considered when it is appropriate. In addition, the Center should have a disaster preparedness plan to minimize total loss of resources in the event of a catastrophic disaster, such as loss of power or potable water, fire, flooding, data breach, pandemic or public health emergency.
10) The Center is required to develop an active program for monitoring and collecting information for reporting purposes and evaluating the impact of their ongoing activities and services provided to the biomedical community. Examples should include tracking user information (such as Institute affiliation and location), sources of funds, associated grant numbers for purchases made with Government funds, and/or outcomes of the studies using obtained animal models and biomaterials. Such information should also be included in progress reports to the NIH.
Additional Information
The P40 application is a multi-component application, with an Overall Component that is the aggregate of the Resource (major), Curation and Informatics (minor), and Applied Research (minor) Components.
Multiple PDs/PIs for the Overall grant are allowed. Typically, one or more of the PDs/PIs of the Overall application also serve as the Core Lead(s) of the Resource Component and can serve as the Project Lead(s) of the Curation and Informatics Component and/or Applied Research Component. The applied research is typically conducted at the applicant institution and not subcontracted.
It is required that Animal and Biological Material Resource Center grants will generate Program Income which will support efforts to enhance the volume of its operations. In general, this means that Renewal (a.k.a. Type 2) applications should recover in the initial year of the proposed grant cycle a greater percentage of operating costs from Program Income than for the last year of the previous grant cycle. Furthermore, each additional year in the proposed grant cycle should reasonably expect to recover a greater percentage of operating costs from Program Income than the average of the previous 5-year project period. Costs specifically associated with the establishment, improvement, or expansion of animal or material distributions and long-term resource maintenance should be recovered from users through a charge schedule acceptable to the NIH. Significant growth of Animal and Biological Material Resource Centers should result from Program Income and not from an ever-increasing P40 award. Note that the Center's use of Program Income is governed by the NIH Grants Policy statement, Section 8.3.2: (http://grants.nih.gov/grants/policy/policy.htm).
An important function of the Animal and Biological Material Resource Center is developing and maintaining the Center’s in-house data management systems in a format that may facilitate its integration with other animal resource databases and community standards for information accessibility and interoperability, and providing adequate staff for curation of newly acquired stocks for collection and animal resource distribution management. These activities will contribute to the implementation of the NIH Strategic Plan for Data Science, which describes actions aimed at modernizing the biomedical research data ecosystem. Biomedical repositories should accept submission of relevant data from the community and generate its own data to store, organize, validate, archive, preserve, and distribute information in compliance with the FAIR (Findable, Accessible, Interoperable, and Reusable) Data Principles. Center should develop plans in accordance with the new NIH Policy for Data Management and Sharing (NOT-OD-22-189) to better position itself for the updated data requirements. In addition, improving access to the Resource Center’s databases as well as developing metrics to evaluate the usage, utility, and impact of a given repository will improve the ability of the center to meet the needs of the biomedical research community.
Most Centers cannot afford to accept all possible donor deposits if the future demand for these materials cannot justify the expense associated with quality control, expansion and archiving of animals and biological materials. For this and additional reasons, Centers must have an External Advisory Board of experts and users who will be responsible for review and evaluation of the Center’s progress, guidance to the PDs/PIs on which potential new animals and biological materials should be accepted for archiving and future distribution, as well as analysis of the Center’s long-term sustainability, biomedical research relevance, and its ability to provide timely and relevant products and services to the research community. The assessments and recommendations should be provided annually to the PDs/PIs as well as NIH Program. The External Advisory Board must be composed of a minimum of 4 members (outside of the PI parent Institution) and must meet a minimum of once per year (the required expertise of the members should be stated, but names of the candidates should not be listed in the application). If a specific External Advisory Board member receives a salary from the P40 grant, s/he should be a non-voting member. Tele- or videoconferencing is encouraged to decrease costs unless the budgeted expense of face-to-face meetings is justified in the application.
See Section VIII. Other Information for award authorities and regulations.
Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
The OER Glossary and the How to Apply - Application Guide provides details on these application types. Only those application types listed here are allowed for this NOFO.
Not Allowed: Only accepting applications that do not propose clinical trials.
The National Institutes of Health (NIH) intends to commit $1.3 M in FY 2023-2025 to fund at least two awards per fiscal year.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
For Renewal (a.k.a. Type 2) applications including Renewal Resubmission applications, no more than a 5 percent increase of direct cost based on a previous non-competing year with the highest direct cost in the prior five-year funding cycle will be accepted. Those calculations do not include the budget for adding a new Curation and Informatics component (up to $300,000 of additional total cost per year) unless the renewal application already had a Curation and Informatics component added via a revision application or existing from the previous project period. In these cases, the 5 percent increase cap for direct cost includes this component.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Higher Education Institutions - Includes all types
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Local Governments
Federal Governments
Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.
This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1.2- Definitions of Terms.
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this NOFO. See the administrative office for instructions if planning to use an institutional system-to-system solution.
It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide, except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts) and where instructions in the How to Apply - Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed.
| Component | Component Type for Submission | Page Limit | Required/Optional | Minimum | Maximum |
|---|---|---|---|---|---|
| Overall | Overall | 6 | Required | 1 | 1 |
| Resource component | Core | 12 | Required | 1 | 1 |
| Curation and Informatics component | Admin Core | 6 | Required | 1 | 1 |
| Applied Research component | Project | 6 | Required | 1 | 2 |
The following section supplements the instructions found in How to Apply- Application Guide and should be used for preparing a multi-component application.
Revision applications must include an Overall component and the components that are affected by the revision. Therefore, the component requirements listed below may not apply to the revision application.
The application should consist of the following components:
When preparing the application, use Component Type ‘Overall’.
All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions, as noted.
Complete entire form.
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Follow standard instructions.
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this NOFO) for the entire application.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.
Specific Aims: State concisely the goals of the proposed project and summarize the expected outcome(s), including the impact that the results of the proposed resource will exert on the research field(s) that it supports.
Research Strategy: Follow the instructions in the SF424 (R&R) Application Guide. In addition, generally describe and justify the need for the Overall Center in the research community, including possible alternatives. Describe how the activities of the Center will enhance reproducible use of the animal models and biological materials it will provide. Describe how the Center will serve the needs of investigators in a variety of research areas where work is sponsored by multiple NIH ICs. Describe how Center activities will assist and promote optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Describe how the Center will coordinate its activities with the development of NAMs, assist in generation of comparative data for decision-making process, contribute to assessing the value and limitations of NAMs and for establishing confidence in NAMs applications. Describe how the Center will be made available to investigators on a national basis. Regarding the plans for the operation and maintenance of the Overall Center, describe how the resources generated by this project will be made available rapidly and efficiently to the NIH-supported research community. Describe how the Center will provide transparency and reproducibility for the information, services, products, and models to be shared. Describe the institutional support for the Overall Center, including plans for long-term continuity. Describe how the Center would be continued beyond this potential grant award. Describe Center efforts for monitoring and collecting information on the impact of their ongoing activities on biomedical research. Such information should also be included in their progress reports to the NIH.
Letters of Support: Letters of Support should be included in the Overall Component (rather than in the Resource or Applied Research Component). Include a Letter of Support from any institution providing space, resources, or financial support other than Program Income from distribution of resources or services.
Resource Sharing Plan:
Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.
Other Plan(s):
All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:
Appendix: Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in How to Apply- Application Guide; any instructions provided here are in addition to the How to Apply - Application Guide instructions.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the How to Apply - Application Guide must be followed.
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply- Application Guide must be followed.
All instructions in the How to Apply- Application Guide must be followed.
When preparing your application, use Component Type ‘Core.'
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete only the following fields:
Enter Human Embryonic Stem Cells in each relevant component.
Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: State concisely the goals of the proposed resource and summarize the expected outcome(s), including the impact that the results of the proposed resource will exert on the research field(s) that it supports.
Research Strategy: Follow the instructions in the SF424 (R&R) Application Guide.
In addition, describe in detail the resources the Center will create, develop, characterize, preserve, and distribute. Describe what quality control procedures will characterize the resources to be provided. Describe in detail how requests for the resources will be handled, including periodic assessments of performance, including milestones and timelines. Describe plans for protocol/methods dissemination to the greater research community, if appropriate.
Describe the Center’s support structure regarding coordination of the Center’s mission; monitoring the timelines for achieving milestones; coordinating and integrating Center activities; implementing a plan for regular evaluation of scientific progress; working with the applicant institution to enhance the visibility and effectiveness of the Center; and ensuring appropriate prioritization of activities, including needed course corrections and problem identification and resolution.
Provide a table that shows how the Center is currently funded, including support from any current P40 grant, Program or Center Income, and other sources such as institutional funds, if applicable. Provide a financial plan, including how the Resource will progress toward recovering increasing support from Program Income. Different Centers have grown at various rates and have accumulated different resources. Therefore, Centers may be at various stages regarding the amount of Program Income that can be generated, which depends on the size and marketability of the resource. The sum of the direct costs requested plus Program Income and Institutional commitment, if applicable, should equal the costs associated with all the functions of the Center. Support for the Center from sources other than the grant and Program Income is not required. The requirement for support in addition to that provided by the grant can be waived by the DCM Director in exceptional circumstances.
Describe the planned meeting format for the Center's External Advisory Board, frequency of meetings, and functions. For Renewal applications, applicants must name and briefly describe the qualifications of their Board members. For New applications, describe the types of expertise that would be sought. New Grantees should contact their potential Board members after their grant is awarded. Potential members of the Board should not be contacted, named, or selected until an award has been made. This stipulation will allow a wider pool of potential reviewers of the applications.
Marketing Plan: The Center should present an effective marketing program, aimed at increasing the awareness of the scientific community regarding its program. It is also incumbent on the Centers to assist the wider community to effectively access and use animals, biomaterials and informatics resources created by the program. The development of new marketing methods based upon evaluation of researcher interest via surveys and methods to analyze interactions with the user interface is highly encouraged. Describe approaches for development of additional methods to raise visibility of resources available from the Center, including social media, targeted publications, and development and implementation of a resource tagging system.
Community Outreach: The Center will also develop a plan to provide community training to enhance the use and utility of the resource. Seminars, presentations, posters or workshops can be an element of this effort. The Center should implement mechanisms that solicit regular feedback and opinion from the user community, including comment boxes and online flash-surveys, and then regularly analyze the results. The Center will also track and report to NIH users’ numbers, web hits and traffic as well as assist in other tracking metrics.
Describe a disaster plan to minimize total loss of resources in the event of a catastrophic disaster, such as loss of power, fire, flooding, data breach, pandemic or public health emergency.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Resource Sharing Plans should be consolidated in the Overall Component.
Appendix: Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
When preparing your application, use Component Type ‘Admin Core.’
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete only the following fields:
Enter Human Embryonic Stem Cells in each relevant component.
Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Budget forms appropriate for the specific component will be included in the application package.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: State concisely the goals of the proposed Curation and Informatics component and summarize the expected outcome(s), including the impact that the results of the proposed component will exert on the ability of biomedical researchers at research centers, academic institutions, the NIH and other federal agencies to advance scientific knowledge in broad areas.
Research Strategy: Follow the instructions in the SF424 (R&R) Application Guide.
In addition, describe how the Curation and Informatics component will generate or support the generation of new information, services, products, models, and NAMs that will improve the Resource. Describe how refinement, improvement, or new application of theoretical concepts, approaches, methodologies, instrumentation, or interventions will be achieved. Describe how the scientific rationale for the Curation and Informatics components will develop new approaches and apply them to the functions of the overall Resource.
The applicant should describe the Center’s in-house data management systems, how they will facilitate integration with other animal resource databases and community standards for information accessibility and interoperability, and how they will provide adequate staff for curation of newly acquired stocks for collection and resource distribution management.
The plan must discuss the following key areas:
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Resource Sharing Plans should be consolidated in the Overall Component.
Appendix: Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
When preparing your application, use Component Type ‘Project.'
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete only the following fields:
Enter Human Embryonic Stem Cells in each relevant component.
Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: State concisely the goals of the proposed Applied Research and summarize the expected outcome(s), including the impact that the results of the proposed Applied Research component will exert on the ability of biomedical researchers at research centers, academic institutions, the NIH and other federal agencies to advance scientific knowledge in broad areas.
Research Strategy: Follow the instructions in the SF424 (R&R) Application Guide. In addition, describe how the Applied Research component will generate new information, services, products, and models that will improve the Resource. Describe how refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions will be achieved. Describe how the scientific rationale for the Applied Research will develop or apply new methodologies to the functions of the Resource Component. At least one of the Applied Research component projects should be focused on generation of comparative data to increase applicability of NAMs and promote integration of the most predictive human disease models. Examples of projects include but are not limited to improvement of methods for animal reproduction, preserving germplasm, health monitoring, testing for animal pathogens, assisted reproductive technologies, phenotyping, developing new models of human diseases or genotyping services, or use of the cell culture, organoids, computational models, or microphysiological systems as complimentary research approaches to traditional animal in vivo models. Describe how the Resource and Applied Research Components synergize beyond what could be achieved through a traditional research project.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Resource Sharing Plans should be consolidated in the Overall Component.
Appendix: Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in How to Apply- Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.
Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.
For information on how applications will be automatically assembled for review and funding consideration after submission, refer to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply - Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in How to Apply - Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.
Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.35.
Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov.
Applicants are required to follow the instructions for post-submission materials, as described in the policy.
Only the review criteria described below will be considered in the review process. Applications submitted to NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
The P40 application is a multi-Component application, with an Overall Component that is the aggregate of the Resource Component, Curation and Informatics Component and the Applied Research Component. Standard numerical scoring will be applied to the Center's Overall Impact, Significance, Investigators, Innovation, Approach, and Environment. Scores should emphasize the resource aspect of the Center. In addition, "Merit Descriptors" will be provided in individual Reviewer’s critiques for individual elements of the Resource, Curation and Informatics and Applied Research Components indicated below. The two potential Merit Descriptors are acceptable or unacceptable.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Specific to this NOFO: Is there a demonstrated need for the Overall Center in the research community? Does the Center serve the needs of investigators in a variety of research areas where work is sponsored by multiple NIH ICs? Do Center activities assist and promote optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research? Will the Center be available to investigators on a national basis?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Specific to this NOFO: Are the design of the Overall Center and the method of providing information, services, products and models innovative? Are there innovative features in the planned Overall Center's interactions with users of the resource, and within the internal and external decision-making processes?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address:
1) the protection of human subjects from research risks, and
2) inclusion (or exclusion) of individuals on the basis of sex, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
Specific to this NOFO: Will the resources generated by this project be made available rapidly and efficiently to the NIH-supported research community? Are appropriate plans in place for assurance of quality control? Are the plans for how the Center will coordinate its activities with development of NAMs, assist in generation of the comparative data for the decision-making process, contribute to assessing the value and limitations of NAMs and for establishing the confidence in NAMs applications adequate? Are appropriate procedures in place for handling requests for the resources, and for the adequate distribution of the resources? Are the timeline and milestones clear and feasible? Are the plans for transparent protocol and methods dissemination to the greater research community appropriate? Is outside scientific expertise available to advise on governance, management, and function of the Resource? Are there reasonable plans for the Center to generate Program Income? Does the application describe a plan to track the impact of the proposed resources or resource-related research on broad research areas? Does the Center have an effective disaster plan to minimize total loss of resources in the event of a catastrophic disaster, such as loss of power, fire, flooding, data breach, pandemic or public health emergency?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Specific to this NOFO: Is there appropriate institutional support for the Overall Center, and are plans for continuity appropriate for the scientific field’s needs?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Additional Review Criteria for Resource Component
The Resource Component will receive a merit descriptor (acceptable or unacceptable) that reflects the following considerations:
Additional Review Criteria for Curation and Informatics Component
The Curation and Informatics component will receive a merit descriptor (acceptable or unacceptable) that reflects the following considerations:
Additional Review Criteria for Applied Research Component
The Applied Research Component will receive a merit descriptor (acceptable or unacceptable) that reflects the following considerations:
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for inclusion. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following three points: (1) a complete description of all proposed procedures including the species, strains, ages, sex, and total numbers of animals to be used; (2) justifications that the species is appropriate for the proposed research and why the research goals cannot be accomplished using an alternative non-animal model; and (3) interventions including analgesia, anesthesia, sedation, palliative care, and humane endpoints that will be used to limit any unavoidable discomfort, distress, pain and injury in the conduct of scientifically valuable research. Methods of euthanasia and justification for selected methods, if NOT consistent with the American Veterinary Medicine Association (AVMA) Guidelines for the Euthanasia of Animals, is also required but is found in a separate section of the application. For additional information on review of the Vertebrate Animals Section, please refer to the Worksheet for Review of the Vertebrate Animals Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions (as applicable), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Renewals (as applicable), the committee will consider the progress made in the last funding period.
For Revisions (as applicable), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Not Applicable
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Appeals of initial peer review will not be accepted for applications submitted in response to this NOFO.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the Council of Councils. The following will be considered in making funding decisions:
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.
Prior to making an award, NIH reviews an applicant’s federal award history in SAM.gov to ensure sound business practices. An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov. NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicant’s integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.
After the peer review of the application is completed, the PD/PI will be able to access their Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement Section 2.4.4 Disposition of Applications.
A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient’s business official.
In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. For more information on the Notice of Award, please refer to the NIH Grants Policy Statement Section 5. The Notice of Award and NIH Grants & Funding website, see Award Process.
Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:
All federal statutes and regulations relevant to federal financial assistance, including those highlighted in NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.
By applying for or accepting federal funds from HHS, recipients certify compliance with all federal antidiscrimination laws and these requirements and that complying with those laws is a material condition of receiving federal funding streams. Recipients are responsible for ensuring subrecipients, contractors, and partners also comply.
Applicants and recipients are strongly encouraged to refer to the NIH Director’s Statement of Priorities, entitled “Advancing NIH’s Mission Through a Unified Strategy.”
Recipients are responsible for ensuring that their activities comply with all applicable federal regulations. Pursuant to 2 CFR 200.340, by accepting an NIH award, the recipient agrees that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates the program goals or agency priorities, in line with 2 CFR 200.340(a)(4).
Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.
Successful recipients under this NOFO agree that:
When recipients, subrecipients, or third-party entities have:
Recipients shall develop plans and procedures, modeled after the NIST Cybersecurity framework, to protect HHS systems and data. Please refer to NIH Post-Award Monitoring and Reporting for additional information.
Not Applicable
Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement Section 8.6 Closeout. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk - Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues.
Grants.gov Support Center - Questions regarding Grants.gov registration and services (e.g., Workspace, subscriptions).
Office of Research Infrastructure Programs (ORIP)
Email: ORIPDCM@mail.nih.gov
Center for Scientific Review (CSR)
Email: NOFOReviewContact@csr.nih.gov
National Heart, Lung, and Blood Institute (NHLBI) – ORIP Team
Email: nhlbioripogm@nhlbi.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.